Likewise, miRNAs can have regulatory actions via multiple pathways in COVID-19 cases [5], and these small molecules might have significant roles in angiotensin-converting enzyme 2 (ACE2) and transmembrane serine protease 2 (TMPRSS2) regulation, which are the receptor and co-receptor of the virus respectively and are responsible for entry and membrane fusion of the virus, thus being a good choice to be inhibited as a therapy. The gene discussed is TMPRSS2; the disease is COVID-19.